Piper Jaffray Companies lowered shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) from an overweight rating to a neutral rating in a report issued on Monday morning. The brokerage currently has $46.00 target price on the specialty pharmaceutical company’s stock.

Other equities analysts also recently issued reports about the company. Cantor Fitzgerald boosted their price objective on Supernus Pharmaceuticals from $25.00 to $27.00 and gave the company an overweight rating in a research report on Thursday, May 11th. Jefferies Group LLC boosted their price objective on Supernus Pharmaceuticals from $35.00 to $45.00 and gave the company a buy rating in a research report on Wednesday, May 31st. Janney Montgomery Scott began coverage on Supernus Pharmaceuticals in a research report on Friday, July 14th. They issued a neutral rating and a $47.00 price objective on the stock. Cowen and Company boosted their price objective on Supernus Pharmaceuticals from $31.00 to $34.00 and gave the company an outperform rating in a research report on Thursday, May 11th. Finally, Stifel Nicolaus boosted their price objective on Supernus Pharmaceuticals from $30.00 to $36.00 and gave the company a buy rating in a research report on Monday, April 3rd. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $46.14.

Supernus Pharmaceuticals (NASDAQ SUPN) opened at 43.05 on Monday. Supernus Pharmaceuticals has a 12 month low of $17.25 and a 12 month high of $44.95. The stock’s 50 day moving average price is $41.41 and its 200-day moving average price is $32.21. The stock has a market cap of $2.16 billion, a PE ratio of 23.16 and a beta of 1.34.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by $0.03. The company had revenue of $57.58 million for the quarter, compared to analysts’ expectations of $57.91 million. Supernus Pharmaceuticals had a net margin of 42.46% and a return on equity of 31.79%. Analysts anticipate that Supernus Pharmaceuticals will post $1.01 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/07/19/supernus-pharmaceuticals-inc-nasdaqsupn-downgraded-to-neutral-at-piper-jaffray-companies.html.

In related news, CFO Gregory S. Patrick sold 54,000 shares of the business’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $32.37, for a total value of $1,747,980.00. Following the completion of the sale, the chief financial officer now owns 54,221 shares in the company, valued at $1,755,133.77. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 5,500 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $34.90, for a total value of $191,950.00. Following the completion of the sale, the vice president now owns 43,887 shares of the company’s stock, valued at approximately $1,531,656.30. The disclosure for this sale can be found here. Insiders have sold 90,097 shares of company stock valued at $3,095,503 in the last 90 days. Company insiders own 6.70% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. raised its stake in Supernus Pharmaceuticals by 156,173.3% in the first quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock worth $209,595,000 after buying an additional 6,692,025 shares in the last quarter. AXA bought a new stake in Supernus Pharmaceuticals during the first quarter worth $6,519,000. Vanguard Group Inc. raised its stake in Supernus Pharmaceuticals by 6.6% in the first quarter. Vanguard Group Inc. now owns 2,516,335 shares of the specialty pharmaceutical company’s stock worth $78,762,000 after buying an additional 156,094 shares in the last quarter. Royce & Associates LP acquired a new position in shares of Supernus Pharmaceuticals during the first quarter worth about $4,069,000. Finally, BNP Paribas Arbitrage SA increased its position in shares of Supernus Pharmaceuticals by 1,265.5% in the first quarter. BNP Paribas Arbitrage SA now owns 138,760 shares of the specialty pharmaceutical company’s stock worth $4,343,000 after buying an additional 128,598 shares during the last quarter. Hedge funds and other institutional investors own 90.95% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.